Home › Stock analysis › ORGO
Organogenesis (ORGO) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
What changed since yesterday
- Closed at $1.00, -9.94% vs the prior close of $1.11.
- Volume 1.27M shares, 1.6x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ORGO slides 9.9% to $1.00, a 52-week low, 5 down days in a row. Closed at $1.00, -9.94% vs the prior close of $1.11. Day range $0.99–$1.13, opened at $1.12.
Last close$1.00-9.94%
Day range0.99–1.13
Open1.12
Volume1.27M
52-week range0.99–7.08
Avg volume (20d)664.10K
ORGO daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — ORGO slides 9.9% to $1.00, a 52-week low, 5 down days in a row
- Closed at $1.00, -9.94% vs the prior close of $1.11. Day range $0.99–$1.13, opened at $1.12.
- Volume was 1.27M shares, 1.6x its 50-day average of 771.10K.
- Price is -34.7% vs its 50-day average ($1.53) and -60.7% vs its 200-day average ($2.54).
- 52-week range $0.99–$7.08; today's close sits at 0% of that range, 85.9% below the 52-week high.
- That makes 5 straight losses.
Oct 15, 2026 — ORGO dips 2.6% to $1.11, a 52-week low, 4 down days in a row
- Closed at $1.11, -2.63% vs the prior close of $1.14. Day range $1.10–$1.14, opened at $1.14.
- Volume was 782.60K shares, 1.0x its 50-day average of 768.66K.
- Price is -28.9% vs its 50-day average ($1.56) and -56.7% vs its 200-day average ($2.56).
- 52-week range $1.10–$7.08; today's close sits at 0% of that range, 84.3% below the 52-week high.
- That makes 4 straight losses.
Oct 14, 2026 — ORGO slides 5.8% to $1.14, a 52-week low, 3 down days in a row
- Closed at $1.14, -5.79% vs the prior close of $1.21. Day range $1.13–$1.20, opened at $1.19.
- Volume was 652.90K shares, 0.8x its 50-day average of 772.23K.
- Price is -28.1% vs its 50-day average ($1.59) and -55.9% vs its 200-day average ($2.58).
- 52-week range $1.13–$7.08; today's close sits at 0% of that range, 83.9% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — ORGO dips 1.6% to $1.21, a 52-week low
- Closed at $1.21, -1.63% vs the prior close of $1.23. Day range $1.20–$1.24, opened at $1.24.
- Volume was 706.90K shares, 0.9x its 50-day average of 773.71K.
- Price is -24.8% vs its 50-day average ($1.61) and -53.6% vs its 200-day average ($2.61).
- 52-week range $1.20–$7.08; today's close sits at 0% of that range, 82.9% below the 52-week high.
Oct 12, 2026 — ORGO slides 4.7% to $1.23, a 52-week low
- Closed at $1.23, -4.65% vs the prior close of $1.29. Day range $1.22–$1.28, opened at $1.28.
- Volume was 506.70K shares, 0.6x its 50-day average of 784.73K.
- Price is -24.7% vs its 50-day average ($1.63) and -53.2% vs its 200-day average ($2.63).
- 52-week range $1.22–$7.08; today's close sits at 0% of that range, 82.6% below the 52-week high.
Oct 9, 2026 — ORGO rises 0.8% to $1.29
- Closed at $1.29, +0.78% vs the prior close of $1.28. Day range $1.27–$1.31, opened at $1.28.
- Volume was 402.10K shares, 0.5x its 50-day average of 787.47K — lighter than usual.
- Price is -22.1% vs its 50-day average ($1.66) and -51.3% vs its 200-day average ($2.65).
- 52-week range $1.25–$7.08; today's close sits at 1% of that range, 81.8% below the 52-week high.
Oct 8, 2026 — ORGO slides 3.0% to $1.28, a 52-week low
- Closed at $1.28, -3.03% vs the prior close of $1.32. Day range $1.25–$1.31, opened at $1.29.
- Volume was 750.00K shares, 1.0x its 50-day average of 780.86K.
- Price is -23.7% vs its 50-day average ($1.68) and -52.1% vs its 200-day average ($2.67).
- 52-week range $1.25–$7.08; today's close sits at 1% of that range, 81.9% below the 52-week high.
Oct 7, 2026 — ORGO dips 1.5% to $1.32
- Closed at $1.32, -1.49% vs the prior close of $1.34. Day range $1.30–$1.39, opened at $1.34.
- Volume was 772.00K shares, 1.0x its 50-day average of 771.42K.
- Price is -22.5% vs its 50-day average ($1.70) and -51.0% vs its 200-day average ($2.69).
- 52-week range $1.27–$7.08; today's close sits at 1% of that range, 81.3% below the 52-week high.
Oct 6, 2026 — ORGO jumps 3.9% to $1.34
- Closed at $1.34, +3.88% vs the prior close of $1.29. Day range $1.29–$1.35, opened at $1.30.
- Volume was 608.70K shares, 0.8x its 50-day average of 767.47K.
- Price is -22.4% vs its 50-day average ($1.73) and -50.7% vs its 200-day average ($2.72).
- 52-week range $1.27–$7.08; today's close sits at 1% of that range, 81.1% below the 52-week high.
Oct 5, 2026 — ORGO slides 3.0% to $1.29, a 52-week low on 2.4x normal volume
- Closed at $1.29, -3.01% vs the prior close of $1.33. Day range $1.27–$1.34, opened at $1.32.
- Volume was 1.83M shares, 2.4x its 50-day average of 754.37K — unusually heavy trading.
- Price is -26.4% vs its 50-day average ($1.75) and -52.9% vs its 200-day average ($2.74).
- 52-week range $1.27–$7.08; today's close sits at 0% of that range, 81.8% below the 52-week high.
Oct 2, 2026 — ORGO slides 5.0% to $1.33, a 52-week low
- Closed at $1.33, -5.00% vs the prior close of $1.40. Day range $1.32–$1.40, opened at $1.40.
- Volume was 536.60K shares, 0.7x its 50-day average of 759.29K.
- Price is -25.0% vs its 50-day average ($1.77) and -51.7% vs its 200-day average ($2.76).
- 52-week range $1.32–$7.08; today's close sits at 0% of that range, 81.2% below the 52-week high.
ORGO latest news & SEC filings
Every SEC filing by or about ORGO in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
Aug 6, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $43.76M (prior year $101.00M) (-56.7% vs Jun 30, 2025)
- Net income: -$96.27M (prior year -$9.39M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.77 (prior year -$0.10) (loss widened vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade ORGO
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Feb 26, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.98% (largest 9.9%).
- Liquidity: about 664.10K shares (≈$663.90K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $1.00 vs a range of $0.99–$7.08 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 8 open-market buys, 17 sales; latest: Arthur S Leibowitz bought 5,000 shares on Mar 9, 2026.
- Latest filings: 8-K Aug 6, 2026; 10-Q Aug 6, 2026; 8-K Aug 6, 2026.
- Share count: 128.67M shares outstanding (Jul 31, 2026), +1.4% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
ORGO market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 1.12 | 1.13 | 0.99 | 1.00 | 1.27M |
| Oct 15, 2026 | 1.14 | 1.14 | 1.10 | 1.11 | 782.60K |
| Oct 14, 2026 | 1.19 | 1.20 | 1.13 | 1.14 | 652.90K |
| Oct 13, 2026 | 1.24 | 1.24 | 1.20 | 1.21 | 706.90K |
| Oct 12, 2026 | 1.28 | 1.28 | 1.22 | 1.23 | 506.70K |
| Oct 9, 2026 | 1.28 | 1.31 | 1.27 | 1.29 | 402.10K |
| Oct 8, 2026 | 1.29 | 1.31 | 1.25 | 1.28 | 750.00K |
| Oct 7, 2026 | 1.34 | 1.39 | 1.30 | 1.32 | 772.00K |
| Oct 6, 2026 | 1.30 | 1.35 | 1.29 | 1.34 | 608.70K |
| Oct 5, 2026 | 1.32 | 1.34 | 1.27 | 1.29 | 1.83M |
| Oct 2, 2026 | 1.40 | 1.40 | 1.32 | 1.33 | 536.60K |
| Oct 1, 2026 | 1.38 | 1.43 | 1.37 | 1.40 | 684.50K |
| Sep 30, 2026 | 1.38 | 1.40 | 1.35 | 1.37 | 543.90K |
| Sep 29, 2026 | 1.36 | 1.40 | 1.36 | 1.38 | 469.60K |
| Sep 28, 2026 | 1.38 | 1.39 | 1.35 | 1.38 | 445.60K |
| Sep 25, 2026 | 1.43 | 1.44 | 1.36 | 1.41 | 603.50K |
| Sep 24, 2026 | 1.45 | 1.46 | 1.39 | 1.42 | 532.70K |
| Sep 23, 2026 | 1.46 | 1.47 | 1.42 | 1.45 | 415.60K |
| Sep 22, 2026 | 1.40 | 1.50 | 1.40 | 1.48 | 411.40K |
| Sep 21, 2026 | 1.41 | 1.41 | 1.38 | 1.40 | 355.90K |
About Organogenesis
Organogenesis (ORGO) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in CANTON, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1661181.
ORGO board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Michael Joseph Driscoll | Director | Mar 11, 2026 |
| Prathyusha Duraibabu | Director | Feb 20, 2026 |
| Jon L Giacomin | Director | Feb 20, 2026 |
| Gary S. Gillheeney | President and CEO | Mar 3, 2026 |
| Michele Ilene Korfin | Director | Feb 20, 2026 |
| Arthur S Leibowitz | Director | Mar 11, 2026 |
| Garrett Lustig | Director | Feb 20, 2026 |
| Glenn H Nussdorf | Director | Dec 18, 2025 |
| Gilberto Quintero | Director | Feb 20, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Patrick Bilbo | Chief Operating Officer | Mar 3, 2026 |
| Robert Cavorsi | Vice President, Strategy | Mar 3, 2026 |
| David Francisco | Chief Financial Officer | Mar 3, 2026 |
| Lori Freedman | Chief Admin. and Legal Officer | Mar 3, 2026 |
| Gary S. Gillheeney | President and CEO | Mar 3, 2026 |
| Brian Grow | Chief Commercial Officer | Apr 24, 2026 |
| Patrick Mcguire | Chief Accounting Officer | Feb 27, 2026 |
| Antonio S. Montecalvo | Vice President, Health Policy | Mar 3, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Mar 9, 2026 | Arthur S Leibowitz | Buy | 5,000 | $2.68 |
| Mar 9, 2026 | Arthur S Leibowitz | Buy | 5,000 | $2.68 |
| Mar 9, 2026 | Arthur S Leibowitz | Buy | 5,000 | $2.68 |
| Mar 9, 2026 | Arthur S Leibowitz | Buy | 5,000 | $2.68 |
| Mar 9, 2026 | Michael Joseph Driscoll | Buy | 10,000 | $2.67 |
| Mar 9, 2026 | Michael Joseph Driscoll | Buy | 10,000 | $2.67 |
| Mar 9, 2026 | Michael Joseph Driscoll | Buy | 10,000 | $2.67 |
| Mar 9, 2026 | Michael Joseph Driscoll | Buy | 10,000 | $2.67 |
| Dec 16, 2025 | Glenn H Nussdorf | Sale | 200,000 | $5.14 |
| Dec 16, 2025 | Glenn H Nussdorf | Sale | 200,000 | $5.14 |
| Dec 16, 2025 | Glenn H Nussdorf | Sale | 200,000 | $5.14 |
| Dec 16, 2025 | Glenn H Nussdorf | Sale | 200,000 | $5.14 |
| Nov 26, 2025 | Glenn H Nussdorf | Sale | 187,957 | $5.29 |
| Nov 26, 2025 | Glenn H Nussdorf | Sale | 187,957 | $5.29 |
| Nov 26, 2025 | Glenn H Nussdorf | Sale | 187,957 | $5.29 |
ORGO financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $564.17M | $37.03M | 0.15 | $-10.31M |
| Dec 31, 2024 | $482.04M | $861.00K | -0.01 | $14.21M |
| Dec 31, 2023 | $433.14M | $4.95M | 0.04 | $30.92M |
| Dec 31, 2022 | $450.89M | $15.53M | 0.12 | $24.86M |
| Dec 31, 2021 | $467.36M | $94.20M | 0.70 | $61.98M |
Latest balance sheet: total assets $406.45M, total liabilities $118.31M, cash $46.10M (as of Jun 30, 2026).
ORGO earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $2.41 |
| May 7, 2026 | 8-K Item 2.02 (results) | $2.53 |
| Feb 26, 2026 | 8-K Item 2.02 (results) | $3.70 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $3.89 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $4.52 |
| May 8, 2025 | 8-K Item 2.02 (results) | $5.34 |
| Feb 27, 2025 | 8-K Item 2.02 (results) | $3.07 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $3.45 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Feb 29, 2024 | 8-K Item 2.02 (results) | — |
| Nov 9, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on ORGO
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.